AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference

On November 20, 2026 AbbVie (NYSE: ABBV) reported it will participate in the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026. Management will participate in a fireside chat at 7:30 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

(Press release, AbbVie, NOV 20, 2026, View Source [SID1234675043])

General Proximity Awarded $9 Million Grant from the Cancer Prevention and Research Institute of Texas (CPRIT) Recognizing the OmniTAC™ Induced Proximity Platform

On November 20, 2026 General Proximity, a biotechnology company discovering and developing the next generation of induced proximity medicines, reported it has been awarded a $9 million Product Development Research Program award from the Cancer Prevention and Research Institute of Texas (CPRIT) in the new technology category, recognizing General Proximity’s OmniTAC induced proximity platform. General Proximity was the only company awarded in this category.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Induced proximity medicines offer a differentiated approach: small molecules that bring two proteins into close physical proximity to induce a desired therapeutic effect, creating opportunities for traditionally undruggable targets.

The CPRIT award recognizes General Proximity’s proprietary OmniTAC platform, which enables unbiased screening for effector proteins capable of modulating disease-relevant targets. Many cancer drivers, including tumor suppressors that are lost or inactivated in tumors, have been considered undruggable because they cannot be addressed with conventional inhibitors. By systematically identifying effector proteins that can be brought into proximity with a target to modulate its function, OmniTAC opens a path to these targets. The award will fund General Proximity’s efforts to advance the OmniTAC-generated lead program into the clinic and to support the clinical validation of the platform.

"We are honored to receive this support from CPRIT, which underscores the potential of our OmniTAC platform and of induced proximity as a powerful new class of medicines," said Armand B. Cognetta III, PhD, Founder & Chief Executive Officer of General Proximity. "This award will help us move our lead program generated by OmniTAC into the clinic. We are also excited to expand our footprint in Texas and build relationships with Texas clinical sites and the state’s life sciences ecosystem."

CPRIT’s Product Development Research Program funds projects at Texas-based or relocating companies developing novel products or services intended to benefit cancer patients. CPRIT received 207 applications this year, 42 of them in the new technology category. CPRIT funded 12 applications in total, only one of which was in the new technology category.

(Press release, General Proximity, NOV 20, 2026, View Source [SID1234675044])

Alterome Therapeutics Presents Preliminary Clinical Data from Ongoing Phase 1/1b Trial of ALTA3263 Demonstrating Antitumor Activity in KRAS-Mutant Colorectal and Pancreatic Cancers at the 38th EORTC-NCI-AACR Symposium

On November 20, 2026 Alterome Therapeutics, Inc., a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapeutics to address oncogenic drivers, reported the presentation of the preliminary clinical data from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b clinical trial evaluating ALTA3263, an orally available KRAS-selective, pan-mutant, active/inactive (ON/OFF) inhibitor, in adult patients with KRAS-mutant advanced solid tumors. These data are being presented today in a late-breaking oral session during the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALTA3263 was designed to inhibit a broad range of KRAS mutations while sparing wild-type HRAS and NRAS, a profile that may support its use in combination with anti-epidermal growth factor receptor (EGFR) inhibitors, other standard-of-care treatments, and targeted therapies.

As of the September 18, 2026 data cutoff, ALTA3263 demonstrated antitumor activity both in combination with cetuximab in patients with advanced metastatic CRC and as monotherapy in patients with advanced metastatic pancreatic ductal adenocarcinoma (PDAC). Pharmacokinetic analyses demonstrated increased linear, approximately dose-proportional exposure from 100 mg to 400 mg twice daily, with exposure at 400 mg twice daily exceeding preclinical steady-state benchmarks. Clinical activity was observed across multiple KRAS mutations, including G12D, G12V, G12A, G13D and Q61H, with the majority of treatment-related adverse events (TRAEs) reported as Grade 1 or Grade 2.

"Preliminary data from the Phase 1 dose-escalation portion of ALTA3263’s trial in CRC and PDAC patients demonstrate its potential to improve upon currently available therapies and address a broad range of KRAS mutations, potentially expanding treatment options for patients who remain in need of more effective and tolerable therapies," said Leo Faoro, M.D., MBA, Chief Medical Officer of Alterome Therapeutics. "These results support our continued focus on advancing ALTA3263 in CRC and PDAC and provide a strong rationale to evaluate ALTA3263 in earlier lines of therapy in combination with standard-of-care regimens and targeted therapies."

ALTA3263 shows potential to broaden targeted therapy in KRAS-mutant CRC

Approximately 50% of colorectal cancers harbor KRAS mutations, making CRC a KRAS-mutant tumor type with significant unmet need in the United States. The most prevalent mutations include KRAS G12D (33%), G12V (22%), G13D (14%), and G12C (7%). Currently approved KRAS-targeted treatment options are limited to patients with KRAS G12C mutations, underscoring the need for therapies that address a broader range of KRAS mutations.

Combining KRAS inhibition with anti-EGFR inhibition may enhance antitumor activity by blocking EGFR-mediated feedback signaling that can limit the effectiveness of KRAS inhibitors in colorectal cancer. The preliminary clinical activity observed with ALTA3263 plus cetuximab provides initial support for this combination strategy in KRAS-mutant CRC.

As of the September 18, 2026 data cutoff, 120 patients had received ALTA3263, including 80 patients treated with monotherapy and 40 patients treated in combination with cetuximab. Patients had received a median of two prior lines of systemic therapy in advanced setting (range: 0–9). Tumor types included PDAC (46%), CRC (42%), non-small cell lung cancer (10%), and others (3%). The distribution of KRAS mutations among enrolled patients was as follows: G12V (40%), G12D (38%), G12A (8%), G13D (7%), Q61H (4%) and other mutations (3%). The maximum tolerated dose has not been reached.

In the Phase 1 dose-escalation portion of the trial, ALTA3263 in combination with cetuximab demonstrated antitumor activity in patients with KRAS-mutant CRC. Among 16 response-evaluable patients treated with ALTA3263 at doses of 200 mg and 300 mg twice-daily in combination with cetuximab who initiated treatment at least 14 weeks before the September 18, 2026 data cutoff and who had a scan post-baseline:

Five patients achieved a partial response (four confirmed and one unconfirmed), resulting in an ORR of 31% (5/16);
15 patients achieved disease control, resulting in a DCR of 94% (15/16);
Tumor regression was observed in 94% of patients with post-baseline target lesions assessment (15/16); and
Responses were observed across multiple KRAS mutations, supporting the design objective of achieving broad mutant allele coverage.
Among 40 patients treated with ALTA3263 plus cetuximab, the majority of TRAEs were mild to moderate (62%), and no patients discontinued treatment due to TRAEs. Grade 3 or higher TRAEs occurred in 33% of patients, and six patients (15%) required dose reductions of ALTA3263 due to TRAEs. The most common TRAEs were diarrhea (83%), dermatitis acneiform (68%), nausea (63%) and vomiting (45%). Grade 3 dermatitis acneiform occurred in 8% of patients. These preliminary findings support our continued evaluation of ALTA3263 in combination with cetuximab.

"The activity observed with ALTA3263 plus cetuximab in KRAS-mutant colorectal cancer is particularly encouraging, with responses across multiple KRAS mutations in a setting where this level of activity has historically been difficult to achieve," said David S. Hong, M.D., Deputy Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. "These early results suggest that ALTA3263, in combination with cetuximab, has the potential to provide a new treatment approach for patients with KRAS-mutant colorectal cancer, where targeted treatment options are limited."

Early monotherapy activity and safety of ALTA3263 in PDAC support evaluation in earlier-line combination regimens

Pancreatic ductal adenocarcinoma is one of the deadliest cancers, with KRAS mutations present in more than 90% of PDAC cases. Despite recent advances in KRAS-directed therapy, there remains a need for targeted therapies with tolerability profiles that may support combination approaches in earlier lines of therapy. The preliminary monotherapy activity and tolerability observed with ALTA3263 support its continued evaluation in PDAC in combination with standard-of-care regimens and targeted therapies.

In the Phase 1 dose-escalation portion of the trial, ALTA3263 monotherapy demonstrated antitumor activity in patients with PDAC treated at doses of 400 mg or 600 mg twice daily. Among 13 response-evaluable patients who initiated treatment at least 14 weeks before the September 18, 2026 data cutoff and had a post-baseline scan:

Three patients achieved confirmed partial responses, resulting in a confirmed objective response rate (ORR) of 23% (3/13);
Disease control rate was 77% (10/13); and
Tumor regression was observed in 83% of patients with post-baseline target lesions assessment (10/12).
Across 80 patients treated with ALTA3263 monotherapy across all tumor types, Grade 3 or higher TRAEs were reported in 15% of patients. The most common TRAEs were diarrhea (51%), vomiting (46%), nausea (45%), and fatigue (31%), predominantly Grade 1 or 2. Dermatitis acneiform was reported in 11% of patients; all events were Grade 1 or 2. One dose-limiting toxicity of Grade 3 diarrhea was observed at 400mg twice daily during monotherapy dose escalation.

The Phase 1/1b, open-label, dose-escalation and multiple-cohort trial of ALTA3263 in adults with advanced solid tumor malignancies with KRAS mutations (NCT06835569) is continuing to enroll patients, with further evaluation of ALTA3263 planned in combination regimens and in earlier treatment settings.

(Press release, Alterome Therapeutics, NOV 20, 2026, View Source [SID1234675030])

PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026

On November 20, 2026 PAQ Therapeutics, a clinical-stage biotechnology company focused on advancing targeted protein degradation to address the unmet medical needs of patients with KRAS-driven cancers, reported first clinical data from its ongoing Phase 1 trial of PT0253 (NCT06797336). Alexander I. Spira, M.D., Ph.D., FACP, FASCO, of NEXT Oncology Virginia, presented the data in a late-breaking oral presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The initial clinical findings demonstrate a differentiated safety profile for PT0253, encouraging monotherapy antitumor activity, including in patients previously treated with (K)RAS-targeted therapies, and promising early combination activity with standard-of-care chemotherapy in first-line metastatic pancreatic cancer. These findings support the potential of KRAS degradation to address resistance mechanisms that may limit KRAS inhibitors, while offering a differentiated approach to sustained KRAS target suppression and improved safety profile.

Monotherapy Dose Escalation

As of October 23, 2026, 44 patients with KRAS G12D-mutant advanced solid tumors had received weekly intravenous PT0253 at doses ranging from 10 to 750 mg. Patients had received a median of 2.5 prior therapies, and 27% had received prior (K)RAS-targeted therapy.

Safety: No dose-limiting toxicities (DLTs) were observed across the full dose range of 10 to 750 mg. At doses of 120 to 750 mg (n=27), treatment-related adverse events (TRAEs) were predominantly Grade 1–2. One patient (4%) experienced a Grade ≥3 TRAE. There were no serious TRAEs or discontinuations due to TRAEs. No PT0253-specific pre-treatment prophylaxis was required.

Antitumor activity: PT0253 monotherapy demonstrated antitumor activity across dose levels, with partial responses (PRs) observed at doses of 120 mg and above in patients with colorectal, pancreatic and lung cancers.

Colorectal cancer: At doses of 120 mg and above, 3 of 6 patients with refractory colorectal cancer achieved partial responses (PRs, unconfirmed), including one patient whose disease had progressed on a prior (K)RAS-targeted agent. These findings are encouraging in the context of the hypothesis that catalytic degradation of KRAS G12D may address EGFR-mediated feedback reactivation associated with KRAS inhibition.
Pancreatic cancer: At doses of 120 mg and above, 3 of 10 (K)RAS therapy-naïve patients had confirmed PRs, with most responses deepening over time. Nine of 10 patients achieved disease control.
Following prior (K)RAS-targeted therapy: Among 12 patients whose disease had progressed on prior (K)RAS-targeted therapy, 6 (50%) achieved disease control, demonstrating encouraging early activity in this difficult-to-treat population.
First-Line Metastatic Pancreatic Cancer: PT0253 + mFOLFIRINOX

Fourteen patients received PT0253 350 mg once weekly in combination with modified FOLFIRINOX (mFOLFIRINOX), a standard-of-care chemotherapy regimen, and 13 remained on treatment as of the October 23, 2026 data cutoff.

Among the 7 patients with at least two scans, 6 achieved objective responses: one confirmed complete response (CR) and five PRs, four of which were confirmed.

The combination was generally well tolerated, with a safety profile consistent with mFOLFIRINOX alone and low gastrointestinal toxicity without PT0253-specific prophylaxis. Median relative dose intensity was 91% for PT0253, while mFOLFIRINOX dose intensity was 75–80% across components, consistent with the expected range for this chemotherapy regimen.

These early findings support further investigation of PT0253 in combination with standard-of-care chemotherapy in first-line pancreatic cancer.

"We are encouraged by these initial clinical data for PT0253. Its differentiated safety profile, monotherapy antitumor activity and promising early combination results support our strategy of advancing KRAS protein degradation as a new therapeutic approach," said Nan Ji, Ph.D., Chief Executive Officer of PAQ Therapeutics. "We look forward to further evaluating PT0253 in pancreatic and colorectal cancer expansion cohorts."

"PT0253 as a monotherapy was well tolerated across the full dose range without pre-treatment prophylaxis. Importantly, in combination with mFOLFIRINOX in first-line pancreatic cancer, patients received chemotherapy at its expected relative dose intensity," said Andrew P. Krivoshik, M.D., Chief Medical Officer of PAQ Therapeutics. "With no dose-limiting toxicities and a high rate of deep responses, the first-line combination data are an important demonstration of combinability with standard-of-care therapy."

"Patients with KRAS G12D-mutant cancers who progress on chemotherapy, and increasingly on KRAS-targeted therapies, have few options," said Dr. Spira. "It is encouraging to see antitumor activity, including a partial response and disease control, in patients whose disease had progressed on prior (K)RAS-targeted therapy. The favorable tolerability observed across the dose range and in combination with standard-of-care chemotherapy is also encouraging. The expansion cohorts will be important to further evaluate these early findings."

About PT0253

PT0253 is an investigational, intravenously administered small-molecule degrader that selectively eliminates the KRAS G12D mutant protein. It is designed to address resistance mechanisms observed with (K)RAS inhibitors, provide sustained KRAS target suppression, and improve safety profile.

The Phase 1 clinical trial of PT0253 is designed to evaluate safety and tolerability, and to determine the maximally tolerated dose and/or recommended Phase 2 dose of PT0253 in adult patients with KRAS G12D-mutant advanced solid tumors.

(Press release, PAQ Therapeutics, NOV 20, 2026, View Source [SID1234675045])

Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona

On November 20, 2026 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, reported updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational, oral, selective WEE1 inhibitor. Interim results will be presented today in a Plenary Oral Session at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, by Timothy A. Yap, MBBS, PhD, FRCP, of The University of Texas MD Anderson Cancer Center, the lead investigator of the study. As of the November 1, 2026 cut off date, 56 patients had received APR-1051 across all dose levels. The interim dataset includes one confirmed (on treatment for more than 10 months at cutoff) and one unconfirmed RECIST 1.1 partial response in patients with PPP2R1A-mutated uterine cancers and five patients with stable disease lasting more than four months. Pharmacodynamic evidence of WEE1 target engagement across multiple dose levels, together with the safety profile and longer follow-up on previously reported clinical activity, support continued dose optimization and continuous once-daily administration. Aprea plans to enroll at least 50 patients with uterine serous carcinoma (USC) or cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC), as dose escalation and backfill expansion enrollment continue, with completion of dose escalation and backfill expansion enrollment expected in the second quarter of 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Updated ACESOT-1051 findings

The presentation, "Interim Results From the First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051)," includes the following findings:

· Clinical activity and durability: Out of the 56 patients who enrolled in this dose escalation trial (including those patients treated at doses believed to be subtherapeutic), 43 are evaluable for response. Two patients with PPP2R1A-mutated uterine cancers achieved RECIST 1.1 partial responses, one confirmed and one unconfirmed. The confirmed response, in a patient with uterine carcinosarcoma treated at 220 mg, was ongoing with treatment beyond 10 months at the time of data cutoff. Sixteen patients had a best overall response of stable disease, five of which had a duration of 4 months or longer. Thirteen patients were still awaiting their initial on-treatment imaging studies at the time of data cutoff.

· WEE1 target engagement: Pharmacodynamic data (PD) from paired skin punch biopsies were stained by IHC for phosphorylation of CDK1-Y15, an established PD marker of WEE1 target engagement. Reductions of at least 50% in pCDK1-Y15 from baseline were observed in 21 of 25 evaluable patients (84%) across multiple dose levels.

· Initial Safety and tolerability: One dose-limiting toxicity (DLT) was observed among 56 treated patients. The DLT was elevation of AST and ALT without elevation in bilirubin in blood tests in a patient with known liver metastases treated at the 50 mg dose level. Grade 3/4 neutrophil count decrease was reported in 4 patients (7%) (1 Grade 3, 3 Grade 4, one of which was serious) all at the 300 mg dose level, with no reported cases of febrile neutropenia. Two patients (4%) experienced Grade 3 pneumonitis, both reported as serious. Other Grade ≥3 treatment-related adverse events included fatigue (5%), lymphocyte count decrease (4%), dyspnea (2%) and diarrhea (2%). The most common all grade treatment-related adverse events were nausea (41%), fatigue (25%), diarrhea (14%) and vomiting (14%).

· Pharmacokinetics: APR-1051 exposure increased with once-daily dosing through 300 mg, with an approximately 18-hour median half-life supporting once-daily dosing. Dose escalation has been modified to include 250 mg and 350 mg dose levels, and Part 1 now provides for up to 110 patients; previously disclosed dose levels of 400 mg and 500 mg are under evaluation.

"These interim results reinforce our focus on advancing APR-1051 in biomarker selected cancers," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "The ongoing confirmed partial response, additional unconfirmed partial response, and prolonged stable disease observed in multiple heavily pre-treated patients provide encouraging early evidence of single-agent clinical activity, supported by WEE1 target engagement and pharmacokinetics compatible with continuous once-daily dosing. Our strategy is to transition from a broad, biomarker-enriched Phase 1 study toward more focused expansion cohorts in patient populations most likely to benefit from APR-1051. Our goal is to evaluate whether APR-1051 can produce clinically meaningful and durable responses in a well-defined patient population with significant unmet medical need."

Expanded enrollment focused on biologically selected cancers

Aprea is refining enrollment to evaluate APR-1051 in populations that may be particularly sensitive to WEE1 inhibition. The Company is working with a diagnostics partner to develop an immunohistochemistry (IHC) assay for cyclin E overexpression, to support patient identification and enrollment of patients with cyclin E-overexpressing PROC. The Company is also expanding the trial to more than 10 clinical sites, from the nine active sites previously disclosed. This effort complements continued evaluation of tumors with CCNE1, CCNE2 or FBXW7 alterations, while an emerging clinical activity signal in PPP2R1A-mutated uterine cancers provides an additional area for evaluation as enrollment expands.

"Patients with advanced uterine and platinum-resistant ovarian cancers need additional treatment options after progression on available therapies," said Eugene Kennedy, MD, Chief Medical Advisor at Aprea. "The observed target engagement and prolonged treatment duration in a patient with a confirmed response provide a rationale to continue evaluating APR-1051 in carefully selected patients. Expanding enrollment in biologically selected populations will help us better characterize clinical activity, assess the consistency of responses and further evaluate tolerability. These data will be important for optimizing dose selection and informing subsequent development."

ACESOT-1051 Trial Design

ACESOT-1051 is a multicenter, open-label Phase 1 study evaluating oral, single-agent APR-1051 administered once daily in 28-day cycles. Part 1 includes dose escalation and backfill expansion of up to 110 patients, using accelerated titration at lower dose levels followed by a Bayesian optimal interval (BOIN) design. Backfill enrollment allows additional patients to be evaluated at dose levels that have cleared safety review. Part 2 is a dose selection optimization stage of up to 80 patients, who will be randomized 1:1 to two selected doses to determine the recommended Phase 2 dose (RP2D).

The primary objectives are to characterize safety and dose-limiting toxicities, determine the maximum tolerated or maximum administered dose, and establish the RP2D. Secondary objectives include pharmacokinetics and preliminary antitumor activity assessed using Response Evaluation Criteria in Solid Tumors (RECIST) or Prostate Cancer Working Group 3 (PCWG3) criteria, as applicable.

For more information on ACESOT-1051, refer to ClinicalTrials.gov identifier NCT06260514.

About APR-1051

APR-1051 is an investigational, orally bioavailable, selective small-molecule inhibitor of WEE1, a kinase that regulates cell cycle checkpoints and helps cancer cells respond to DNA damage. APR-1051 was designed to minimize off-target inhibition of the PLK family of kinases, with the goal of improving its therapeutic profile. Its potential differentiation remains under clinical evaluation.

(Press release, Aprea, NOV 20, 2026, View Source [SID1234675031])